Decreased TAZ expression in MM cell lines and patient samples predicts worse outcomes. (A) Expression data comparing normal plasma cells (NPCs) from healthy subjects (n = 22), MGUS (n = 44), SMM (n = 12), and MM (n = 351), combining data from GSE5900 and GSE2658 using probe set 202134_s_at. Data are presented using box-and-whisker plots according to the Tukey method. The Student t test was used to evaluate significance: **P ≤ .01 and ***P ≤ .001. (B) Overall survival curve relative to TAZ expression in individuals affected by MM, obtained from http://www.canevolve.org/AnalysisResults/AnalysisResults.html and based on GSE2658 (log-rank test). Optimal cutoff determined using Cutoff Finder (http://molpath.charite.de/cutoff).²⁸  (C) Immunoblot analysis of HMCLs for protein expression of TAZ, YAP, LATS1, and MST1 relative to A549 cells. (D) mRNA expression of TAZ, YAP, LATS1, and MST1 relative to A549 cells in HMCLs. A.U., arbitrary unit; HR, hazard ratio; ns, not significant.